Clinical Trial Update: Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy [Phase 2]

View source ↗

Summary

Phase 2 dose-finding study of BI54903 inhaled corticosteroid for asthma inadequately controlled on SABA; terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• BI54903 (BI54903)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 2 | Status: TERMINATED | Results posted: 2022-06-23